Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 173

1.

Cannabinoid agonists but not inhibitors of endogenous cannabinoid transport or metabolism enhance the reinforcing efficacy of heroin in rats.

Solinas M, Panlilio LV, Tanda G, Makriyannis A, Matthews SA, Goldberg SR.

Neuropsychopharmacology. 2005 Nov;30(11):2046-57.

5.
6.

Reinforcing and neurochemical effects of cannabinoid CB1 receptor agonists, but not cocaine, are altered by an adenosine A2A receptor antagonist.

Justinová Z, Ferré S, Redhi GH, Mascia P, Stroik J, Quarta D, Yasar S, Müller CE, Franco R, Goldberg SR.

Addict Biol. 2011 Jul;16(3):405-15. doi: 10.1111/j.1369-1600.2010.00258.x.

7.

Fatty acid amide hydrolase inhibition heightens anandamide signaling without producing reinforcing effects in primates.

Justinova Z, Mangieri RA, Bortolato M, Chefer SI, Mukhin AG, Clapper JR, King AR, Redhi GH, Yasar S, Piomelli D, Goldberg SR.

Biol Psychiatry. 2008 Dec 1;64(11):930-7. doi: 10.1016/j.biopsych.2008.08.008.

8.

Intravenous self-administration of the cannabinoid CB1 receptor agonist WIN 55,212-2 in rats.

Fattore L, Cossu G, Martellotta CM, Fratta W.

Psychopharmacology (Berl). 2001 Aug;156(4):410-6.

PMID:
11498718
9.

Effects of endocannabinoid neurotransmission modulators on brain stimulation reward.

Vlachou S, Nomikos GG, Panagis G.

Psychopharmacology (Berl). 2006 Oct;188(3):293-305.

PMID:
16953388
10.

CB1 receptor agonist and heroin, but not cocaine, reinstate cannabinoid-seeking behaviour in the rat.

Spano MS, Fattore L, Cossu G, Deiana S, Fadda P, Fratta W.

Br J Pharmacol. 2004 Oct;143(3):343-50.

11.

Evaluation of the role of nicotinic acetylcholine receptor subtypes and cannabinoid system in the discriminative stimulus effects of nicotine in rats.

Zaniewska M, McCreary AC, Przegaliński E, Filip M.

Eur J Pharmacol. 2006 Jul 1;540(1-3):96-106.

PMID:
16730696
12.

The endogenous cannabinoid anandamide has effects on motivation and anxiety that are revealed by fatty acid amide hydrolase (FAAH) inhibition.

Scherma M, Medalie J, Fratta W, Vadivel SK, Makriyannis A, Piomelli D, Mikics E, Haller J, Yasar S, Tanda G, Goldberg SR.

Neuropharmacology. 2008 Jan;54(1):129-40.

13.

Evaluation of WIN 55,212-2 self-administration in rats as a potential cannabinoid abuse liability model.

Lefever TW, Marusich JA, Antonazzo KR, Wiley JL.

Pharmacol Biochem Behav. 2014 Mar;118:30-5. doi: 10.1016/j.pbb.2014.01.002.

14.

Previous exposure to THC alters the reinforcing efficacy and anxiety-related effects of cocaine in rats.

Panlilio LV, Solinas M, Matthews SA, Goldberg SR.

Neuropsychopharmacology. 2007 Mar;32(3):646-57.

15.

Evaluation of interactions between cannabinoid compounds and diazepam in electroshock-induced seizure model in mice.

Naderi N, Aziz Ahari F, Shafaghi B, Najarkolaei AH, Motamedi F.

J Neural Transm (Vienna). 2008 Nov;115(11):1501-11. doi: 10.1007/s00702-008-0076-x.

PMID:
18575801
16.

The opioid antagonist naltrexone reduces the reinforcing effects of Delta 9 tetrahydrocannabinol (THC) in squirrel monkeys.

Justinova Z, Tanda G, Munzar P, Goldberg SR.

Psychopharmacology (Berl). 2004 Apr;173(1-2):186-94.

PMID:
14668977
18.
19.
20.

Nicotinic facilitation of delta9-tetrahydrocannabinol discrimination involves endogenous anandamide.

Solinas M, Scherma M, Tanda G, Wertheim CE, Fratta W, Goldberg SR.

J Pharmacol Exp Ther. 2007 Jun;321(3):1127-34.

Items per page

Supplemental Content

Support Center